PROSTVAC-V/TRICOM

BIOLOGICAL3 trials

Sponsors

National Cancer Institute (NCI)

Conditions

Neoplasms, ProstateProstate CancerProstatic Neoplasms

Phase 1

Vaccine and Antibody Treatment of Prostate Cancer

CompletedNCT00113984

National Cancer Institute (NCI)Prostatic Neoplasms

Start: 2005-06-08End: 2011-12-01Updated: 2019-12-16

Phase 2

Vaccine Therapy With PROSTVAC/TRICOM and Flutamide Versus Flutamide Alone to Treat Prostate Cancer

CompletedNCT00450463

National Cancer Institute (NCI)Prostate Cancer

Start: 2007-02-23End: 2017-06-08Updated: 2018-11-29

Vaccine Plus Booster Shots in Men With Prostate Cancer Undergoing Treatment With Radical Prostatectomy

CompletedNCT02153918

National Cancer Institute (NCI)Neoplasms, Prostate, Prostate Cancer, Prostatic Neoplasms

Start: 2014-05-31End: 2018-01-16Updated: 2018-10-12

Related Papers

587 Nivolumab increased vaccine induced T-cell infiltration in Prostate cancer

Regular and Young Investigator Award Abstracts2023-10-31

Flutamide With or Without PROSTVAC in Non-metastatic Castration Resistant (M0) Prostate Cancer

The Oncologist2023-05-0312 citations

MP67-16 SURGICAL OUTCOMES IN PATIENTS RECEIVING NEOADJUVANT VACCINE THERAPY (PROSTVAC) PRIOR TO RADICAL PROSTATECTOMY: A PHASE II EXPERIENCE

The Journal of Urology2023-03-23

Neoadjuvant PROSTVAC prior to radical prostatectomy enhances T-cell infiltration into the tumor immune microenvironment in men with prostate cancer

Journal for ImmunoTherapy of Cancer2020-03-0175 citations

Effect of rilimogene galvacirepvec/rilimogene glafolivec on intra/peritumoral immune infiltrate in patients with localized prostate cancer undergoing radical prostatectomy.

Journal of Clinical Oncology2018-05-202 citations

Combining active immunotherapy and immune checkpoint inhibitors in prostate cancer.

Journal of Clinical Oncology2015-05-204 citations

Combining active immunotherapy and immune checkpoint inhibitors in prostate cancer.

Journal of Clinical Oncology2015-03-0112 citations

Abstract 5012: A combination trial of vaccine plus ipilimumab in metastatic castration-resistant prostate cancer patients: Immune correlates

Cancer Research2014-10-011 citations

Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial.

2012-02-10253 citations